A new anti-gout drug has exploded!

Three pharmaceutical companies applied for consistency evaluation of benzbromarone tablets.
Yichang East Sunshine Yangtze River Pharmaceutical's products have been successfully approved; Shanghai Xinyi Wanxiang Pharmaceutical and China Resources Shuanghe Pharmaceutical submitted supplementary applications for consistency evaluation of allopurinol tablets , Shanghai Xinyi Wanxiang Pharmaceutical's products have been reviewed
.

Febuxostat has been included in the third batch of centralized procurement.
Jiangsu Wanbang Biochemical, Hengrui Pharmaceutical, and Hangzhou Zhuyangxin Pharmaceutical were selected
.
The third batch of centralized procurement will be implemented successively from the end of 2020 to the beginning of 2021.
It is expected that the sales scale and market pattern of febuxostat terminals in China's public medical institutions will change in 2021
.

Conclusion

At present, there are few types of anti-gout drugs on the market in China, and some drugs have certain limitations in efficacy and safety.
For example, benzbromarone has good efficacy, but there is certain liver damage.
Febuxostat is safe in the kidneys.
It is superior to allopurinol in terms of sex, but it has been shown to increase the risk of adverse cardiovascular CV events in clinical practice and so on
.

Chinese patients with hyperuricemia and gout still have an urgent need for efficient and safe uric acid-lowering drugs.
Hengrui, Chengdu Haichuang Pharmaceutical, Yingli Pharmaceutical, Simcere Pharmaceutical, Changchun Jinsai, Sansheng Pharmaceutical, Kangyuan The pharmaceutical industry and other companies are deploying new anti-gout drug research and development, which is expected to bring new treatment options to patients with hyperuricemia and gout
.

Note: The statistics are as of July 14, if there are any omissions, please correct me!